Diagnosed with SMM, SPB, or MGUS?
Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Pre-Myeloma »
- Pre- Myeloma Diagnosis – Non-Hodgkin Lymphoma w/ MGUS
Pre- Myeloma Diagnosis – Non-Hodgkin Lymphoma w/ MGUS
“The results showed that curcumin strongly inhibited proliferation of Raji cells, (lymphoma) for Raji cells was 22.8 +/- 1.82 micromol/L and curcumin induced Raji cell apoptosis in a time- and dose-dependent manner…”
Dear Cancer Coach- I am in remission from non-Hodgkin Lymphoma (NHL). I was in near remission after the third chemo treatment of R-CHOP. When first diagnosed with Lymphoma a bone marrow biopsy was performed. There was no Lymphoma in my bone marrow but there evidence of monoclonal gammopathy of undetermined significance ( MGUS.)
After completing the 6 th R-CHOP treatment the MGUS was knocked down to 3 percent and the Lymphoma was gone. Of course the drs advised a wait-and-see course but I feel that I should take some action to prevent it from developing any more than 3 percent. If you can advise I would be so grateful.
Dear NHL Survivor-
Your situation is sort of backwards. In a good way. A person is supposed to be diagnosed with MGUS and then progress to full-blown multiple myeloma or NHL. Your chemotherapy has put your NHL in complete remission. Which is the goal. My interpretation of the presence of MGUS in your blood, however minor, means that, like multiple myeloma and MGUS, the presence of a “blood disorder” is an indicator of the possibility of NHL relapsing.
Oncology recommends a “wait and see” approach to MGUS because it is not cancer, MGUS is a non-malignant, asymptomatic blood disorder. I agree with you however, that all MGUS patients should do what they can to prevent a diagnosis of a full-blown blood cancer (MM or NHL). I know of both MGUS and SMM survivors who have been living with these blood cancer precursors for 15 years or more.
As you can see from the study linked below, curcumin is apoptotic to NHL in the same way that it is apoptotic to MM.
If you would like the pre-MM cancer coaching guides all I ask is that you keep me abreast of your progress.
Let me know,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Recommended Reading:
- Can MGUS cause more cancers?
- Diagnostic Testing for MGUS
- Single Plasmacytoma, MGUS or SMM? To treat or watchful waiting?
Anticancer effect of curcumin on human B cell non-Hodgkin’s lymphoma.
“To explore the anticancer effect of curcumin on human B cell non-Hodgkin’s lymphoma and compare its effects on human B cell non-Hodgkin’s lymphoma cells and normal peripheral blood mononuclear cells (NPBMNCs).
MTT assay was used to study the effect of curcumin on the growth of Raji cells and NPBMNCs. The effect of curcumin on the apoptosis of Raji cells and NPBMNC were studied by flow cytometry and TDT-mediated dUTP nick and labeling (TUNEL).
The effect of curcumin on the cell cycle of Raji cells were examined by propidium iodide staining flow cytometry.
The results showed that curcumin strongly inhibited proliferation of Raji cells, 24 h IC50 for Raji cells was 22.8 +/- 1.82 micromol/L and curcumin induced Raji cell apoptosis in a time- and dose-dependent manner. Raji cells treated with curcumin showed G0/G1 or G2/M phase increase and S phase decrease.
However, curcumin did not demonstrate apparent proliferation inhibition and apoptosis induction in NPBMNCs. It was concluded that curcumin is able to inhibit the proliferation of Raji cells by regulating the cell cycle and inducing the cell apoptosis. Morever, curcumin has low toxicity on NPBMNCs but can selectively induce apoptosis in Raji cells.”
MGUS and MM, NHL
“To assess the cancer risk of monoclonal gammopathy of undetermined significance (MGUS) we identified 1229 cases of MGUS in the period 1978 to 1993. Data on cancer occurrence in the MGUS cohort were obtained from the Danish Cancer Registry.
The expected numbers of cancer cases were calculated from age-, sex-, county-, and period-specific cancer incidence rates. In the MGUS cohort 64 new cancers with a known association with M-components were diagnosed versus 5.0 expected giving a standardized incidence ratio (SIR) of 12.9 (95% confidence interval, 9.9-16.5).
The relative risks of developing
- multiple myeloma (SIR 34.3),
- Waldenström’s macroglobulinemia (SIR 63.8), and
- non-Hodgkin’s lymphoma (SIR 5.9)
were significantly increased and independent of time passed from detection of the M-component. The relative risk of chronic lymphocytic leukemia was not significantly increased, SIR 2.7 (0.5-7. 7).
Among cancer sites without known association with M-components 141 cases were observed versus 94.6 expected giving a SIR of 1.5 (1. 3-1.8). This enhanced risk was seen for several non-hematological cancer sites but for most cancer sites the risk was dependent on time passed from detection of the M-component, indicating a bias rather than a causal role of MGUS.